MichaelSSaagMD

Infectious Disease • Birmingham, AL

HIV/AIDS Medicine

Professor of Medicine, University Alabama

Join to view full profile

Dr. Saag is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Saag's full profile

Already have an account?

Office
619 19th St S
Birmingham, AL 35233
Phone+1 205-934-6600

Education & Training

University of Alabama Medical CenterFellowship, Infectious Disease, 1985 - 1987
University of Alabama Medical CenterResidency, Internal Medicine, 1981 - 1984
University of Louisville School of MedicineClass of 1981

Certifications & Licensure

AL State Medical License 1982 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Infectious Disease

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2002-2014
Elected Member The American Society for Clinical Investigation, 1997
Whos Who in Medicine and Healthcare Marquis Whos Who

Clinical Trials

A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis
Completed
Not Applicable
A Phase II Double-Blind Study of Two Doses of SC-49483 in Combination With Zidovudine (ZDV) Versus ZDV
Completed
Phase 2
A Study to Compare Two Anti-HIV Drug Combinations Start of enrollment: 1999 Oct 01
Completed
Phase 3
Safety and Activity of the Oral HIV Entry Inhibitor AMD11070 in HIV Infected Patients Start of enrollment: 2004 Nov 01
Completed
Phase 1, Phase 2
Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V Mutation Start of enrollment: 2006 Mar 31
Completed
Phase 1, Phase 2
Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A Start of enrollment: 2006 Sep 01
Completed
Phase 2
Study of the Efficacy and Safety of Apricitabine, a New NRTI, to Treat Drug-resistant HIV Infection Start of enrollment: 2008 Feb 01
Terminated
Phase 2, Phase 3
HIV Viral Load Monitoring in Resource-Poor Settings Start of enrollment: 2006 Dec 01
Completed
Not Applicable
Evaluation of PTB Screening in ANC in Lusaka, Zambia Start of enrollment: 2011 Nov 01
Completed
Not Applicable
Join now to see all

Publications & Presentations

PubMed

55 citations
Misguided Use of Hydroxychloroquine for COVID-19: The Infusion of Politics Into Science.
Michael S. Saag
JAMA. 2020-12-01
1464 citations
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection
Brandon F. Keele, Elena E. Giorgi, Jesus F. Salazar-Gonzalez, Julie M. Decker, Kimmy T. Pham
Proceedings of the National Academy of Sciences of the United States of America. 2008-05-27
72 citations
Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-Infected Adults
Jeffrey M. Jacobson, Jacob Lalezari, Melanie A. Thompson, Carl J. Fichtenbaum, Michael S. Saag
Antimicrobial Agents and Chemotherapy. 2010-10-01

Journal Articles

Misguided Use of Hydroxychloroquine for COVID-19
Michael Saag, MD, JAMA
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
Michael S Saag, Melanie A Thompson, Constance A Benson, Susan P Buchbinder, Joseph J Eron, Donna M Jacobsen, JAMA
Alcohol Use Patterns and Subsequent Sexual Behaviors Among Women, Men Who Have Sex with Men and Men Who Have Sex with Women Engaged in Routine HIV Care in the United S...
Heidi E Hutton, Karen L Cropsey, Katerina Christopoulos, W Christopher Mathews, Geetanjali Chander, Michael Saag, Heidi M Crane, AIDS and Behavior
A 9-Point Risk Assessment for Patients Who Inject Drugs Requiring Intravenous Antibiotics May Allow Health Systems to Focus Inpatient Resources on Those at Greatest Ri...
Peter S Lane, Benjamin B Taylor, Ellen F Eaton, Rachael A Lee, Cayce S Paddock, Michael S Saag, Clinical Infectious Diseases
HIV Viral Suppression Trends over Time Among HIV-Infected Patients Receiving Care in the United States, 1997 to 2015: A Cohort Study
Kenneth H Mayer, W Christopher Mathews, Michael J Mugavero, Katerina A Christopoulos, Richard D Moore, Benigno Rodriguez, Joseph J Eron, Michael S Saag, Mari M Kitahat..., Annals of Internal Medicine
Join now to see all

Lectures

Baseline Genotype Testing to Assess Drug Resistance Before Beginning HIV Treatment—Reply
University of Alabama at Birmingham, Birmingham, AL - 5/15/2014

Press Mentions

HIV and Opioid Use Disorder: Screening Tools, Chronic Pain Management, and Access to Care in the Outpatient SettingMay 10th, 2023
The COVID Vaccine Success Story as a Springboard for Future ResearchJanuary 24th, 2023
Local Health Officials Plan to Increase Monkeypox VaccinationsAugust 12th, 2022
Join now to see all

Grant Support

Alabama-Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases2007–2012
Integration Of Evidence-Based Alcohol Interventions Into HIV CareNational Institute On Alcohol Abuse And Alcoholism2011
Recent Advances In AIDS And HIV ResearchNational Institute Of Allergy And Infectious Diseases2009–2011
Administrative CoreNational Institute Of Allergy And Infectious Diseases2009–2011
Unsolicited R24 For The Cfar-Network Of Integrated Clinical Sciences, CnicsNational Institute Of Allergy And Infectious Diseases2006–2011
UAB Center For AIDS ResearchNational Institute Of Allergy And Infectious Diseases2004–2011
AdministrativeNational Institute Of Allergy And Infectious Diseases2008
ACTG A5229National Center For Research Resources2007
ACTG A5209 Ezetimibe (ZETIA) In Combination With Statin Therapy For The TreatmenNational Center For Research Resources2006–2007
ACTG A5001 (V 30)National Center For Research Resources2006–2007
A5202, Final Version 10, 05/05/05: Initial Therapy With Different AntiretroviraNational Center For Research Resources2006–2007
Silcaat V 40National Center For Research Resources2005–2007
FRAM 2National Center For Research Resources2005–2007
Amd11070 In Hiv-Positive Subjects (A5210)National Center For Research Resources2005–2007
ACTG A5146National Center For Research Resources2005–2007
ACTG A5068National Center For Research Resources2004–2007
Recent Advances In AIDS And HIV ResearchNational Institute Of Allergy And Infectious Diseases2003–2007
Adult AIDS Clinical Trials GroupNational Institute Of Allergy And Infectious Diseases2000–2007
ACTG A5142, V 20National Center For Research Resources2006
ACTG A5186National Center For Research Resources2005–2006
ACTG A5178 (Slam-C)National Center For Research Resources2005–2006
ACTG A5174 Improving Immune Reconstitution With Growth Hormone In Hiv-InfectedNational Center For Research Resources2005
ACTG A5142, V 20 Comparison Of Lopinavir/Ritonavir PLUS Efavirenz VS Lopinavir/National Center For Research Resources2005
ACTG A5001 (V 20) Adult AIDS Clinical Trials Group Longitudinal Linked RandomizNational Center For Research Resources2005
ACTG 5095 Comparison Of Three Protease Inhibitor-Sparing Regimens For The InitiaNational Center For Research Resources2005
ACTG A5181National Center For Research Resources2004–2005
Improving Immune Reconstitution With Growth HormoneNational Center For Research Resources2004
Comparison Of Lopinavir/Ritonavir PLUS EfavirenzNational Center For Research Resources2004
Adult AIDS Clinical Trials Group Longitudinal LinkedNational Center For Research Resources2004
ACTG 5095 Comparison Of Three Protease InhibitorNational Center For Research Resources2004
Core--ClinicalNational Institute Of Allergy And Infectious Diseases1998–2002
Viral/Lymphocyte Dynamics In HIV-1 Infected PatientsNational Center For Research Resources2000
T20 Administered To HIV1 Positive AdultsNational Center For Research Resources1998–1999
Women'S Health AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
Pharmacology AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
Outreach AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
Outcomes Committee AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
Neurology AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
Immunology And Immune Based Therapy AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
HIV Disease Research AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
Core--Advanced Technology LaboratoriesNational Institute Of Allergy And Infectious Diseases1997–1999
Complications Of HIV Disease AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
Adult AIDS Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases1992–1999
Oral Prednisone In HIV Infection With Unexplained Weight LossNational Center For Research Resources1996–1997
Antiviral Activity Of GEM 91 In HIV Positive AdultsNational Center For Research Resources1996
Itraconazole And Fluconazole In Relapse Of Aids-Related Cryptococcal MeningitisNational Center For Research Resources1995
AMP B/Flucytosin VS AMP B/Fluconazole In Acute Cryptococcal MeningitisNational Center For Research Resources1995
AIDS Clinical TrialsNational Institute Of Allergy And Infectious Diseases1994–1995
Recombinant Cd4-Immunoglobulin In HIV Infection And Sensitivity To Rcd4-IggNational Center For Research Resources1993–1995
Trimetrexate W/Leucovorin CA Rescue VS Pentamidine In AIDSNational Center For Research Resources1992–1995
SCH 39304 To Patients With Advanced HIV InfectionNational Center For Research Resources1992–1995
Randomized Double-Blind Protocol In Acute Crytococcal MeningitisNational Center For Research Resources1992–1995
L-697,661 Compared To AZT In HIV Sero-Positive PatientsNational Center For Research Resources1992–1995
Pharmacokinetics In HIV Infected AdultsNational Center For Research Resources1993
SCH 39304 For Acute Cryptococal Meningitis In HIV Infected PatientsNational Center For Research Resources1992–1993
Trimetrexate W/Leucovorin CA Rescue VS Trimethoprim/SulfamethoxazoleNational Center For Research Resources1990
Trimetrexate VS IV Pentamidine In AIDS Patients With PCP Refractory To T/SNational Center For Research Resources1990
Pharmacokinetic Study Of Single 600mg Oral Dose Of Sch39304National Center For Research Resources1990
Maintenance Fluconazole And Amphotericin B For Crypto Meningitis In AIDSNational Center For Research Resources1990